Compare RAPP & PLGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | RAPP | PLGO |
|---|---|---|
| Founded | 2022 | N/A |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | | Property-Casualty Insurers |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2024 | 2023 |
| Metric | RAPP | PLGO |
|---|---|---|
| Price | $45.71 | $25.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $48.50 | N/A |
| AVG Volume (30 Days) | ★ 302.9K | 286.6K |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.34 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.86 | $22.80 |
| 52 Week High | $46.72 | $26.34 |
| Indicator | RAPP | PLGO |
|---|---|---|
| Relative Strength Index (RSI) | 65.49 | 59.34 |
| Support Level | $33.54 | $24.19 |
| Resistance Level | N/A | $26.04 |
| Average True Range (ATR) | 2.44 | 0.69 |
| MACD | 0.22 | -0.08 |
| Stochastic Oscillator | 94.69 | 62.79 |
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.